New cervical cancer screening test has 100% accuracy in trial

  • We earn a commission for products purchased through some links in this article.

  • According to a study, a new test for cervical cancer has been found to outperform both the Pap smear test and HPV test at a reduced cost.

    Researchers found the new cervical cancer test detected 100% of the cancers in a randomised clinical screening trial of 15,744 women.

    The study was published in the International Journal of Cancer and was conducted by Queen Mary University of London.

    In a study of women aged 25-65 in Canada, the new ‘epigenetics-based’ cervical cancer test was compared with Pap smear tests and HPV tests and it was explored how effectively it predicted the development of cervical cancer up to five years in advance.

    The new test detected 100% of the eight invasive cervical cancers that developed in the women throughout the trial whereas the Pap smear test detected 25% of the cancers and the HPV test detected 50%.

    It is no wonder the new ‘epigenetics-based’ test is being labelled “significantly better.”

    Lead researcher Professor Attila Lorincz from Queen Mary University of London contributed towards the development of the world’s first HPV test in 1988. She is stunned by how well the new test detects cervical cancer.

    She said, “This is an enormous development… it is the first time that anyone has proven the key role of epigenetics in the development of a major solid cancer using data from patients in the clinic. Epigenetic changes are what this cervical cancer test picks up and is exactly why it works so well.”

    The new test studies naturally occurring chemical markers that are found on top of the DNA. This is what makes up its ‘epigenetic profile.’

    According to Professor Lorincz, this is a key discovery, “In contrast to what most researchers and clinicians are saying, we are seeing more and more evidence that it is in fact epigenetics, and not DNA mutations, that drives a whole range of early cancers, including cervical, anal, oropharyngeal, colon, and prostate.”

    It has been suggested the number of visits to the doctor and screening appointments would be reduced if this new test was to be used in clinics and it is also predicted to be cheaper than the Pap smear.

    It is thought the findings are going to‘revolutionise’ screening.